Update Your Profile Member Spotlights Refer a Member: IASP Champions Join a Special Interest Group (SIG) Find a Chapter Join Now
PAIN PAIN Reports Pain Research Forum Papers of the Week Webinars and Podcasts Events
Online Learning - PERC Webinars & Podcasts Curricula Graduate Opportunities Events
RELIEF News Resources for Living with Pain Global Alliance of Partners in Pain Advocacy (GAPPA) Events
Support IASP Sponsor an Event Become a Partner
< BACK TO ARCHIVE
POW ARCHIVE WEEK: Papers: 19 Sep 2020 - 25 Sep 2020
STUDY TYPE:Human Studies, Pharmacology/Drug Development
PAIN TYPE:Migraine/Headache
DATE PUBLISHED: 2020 Sep 21
JOURNAL:J Headache Pain
PUBMED: http://www.ncbi.nlm.nih.gov/pubmed/32958075?dopt=Abstract
Volume:21
ISSUE:1
We evaluated the efficacy of fremanezumab, a fully humanized monoclonal antibody that selectively targets calcitonin gene-related peptide, in patients with chronic migraine (CM) with and without medication overuse (MO).
